Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): a multi-cohort adaptive phase I clinical trial.

Research output: Unpublished contribution to conferencePoster

Original languageEnglish
Publication statusPublished - 2121
EventESMO CONGRES -
Duration: 16 Sep 202121 Sep 2021

Conference

ConferenceESMO CONGRES
Period16/09/2121/09/21

Cite this